Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. This is an ASCO Meeting Abstract from the 2020 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results